Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc." Results 41 - 60 of 292
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jun 2019, 5:00 am by Dani Alexis Ryskamp
Merrell Dow Pharmaceuticals when it comes to qualifying expert witnesses. [read post]
18 Jun 2019, 5:00 am by Anjelica Cappellino
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), which focuses on an analysis of enumerated factors when determining expert admissibility. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
21 Mar 2019, 4:00 am by Anjelica Cappellino
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), which listed several factors that a court may consider when determining the admissibility of an expert. [read post]
22 Jan 2019, 2:30 am by Tinker Ready
Ryan Gabrielson ProPublica Originally published at ProPublica January 17 , 2019 At the FBI Laboratory in Quantico, Virginia, a team of about a half-dozen technicians analyzes pictures down to their pixels, trying to determine if the faces, hands, clothes or cars of suspects match images collected by investigators from cameras at crime scenes. [read post]
28 Dec 2018, 2:22 pm by Schachtman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), appealed a Ninth Circuit ruling that the Frye rule survived, and was incorporated into, the enactment of a statutory evidentiary rule, Rule 702. [read post]
17 Nov 2018, 12:10 pm by Schachtman
To be sure, judges have often poorly expressed their reasoning for deciding scientific evidentiary issues, and perhaps poor communication or laziness by judges was responsible for Rothman’s interest in joining the Daubert fray. [read post]
13 Nov 2018, 7:31 am by Kaylin S. Grey
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) (“Daubert”). [read post]
6 Nov 2018, 5:00 am by Anjelica Cappellino
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), which enumerated a non-exhaustive list of factors for the courts to consider when determining whether to admit expert testimony. [read post]
31 Oct 2018, 10:04 am by Schachtman
In some instances, especially in studies pharmaceutical adverse outcomes, there is the danger that the hypothesized outcome is also a feature of the underlying disease being treated. [read post]